Cargando…
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. FL is an incurable disease with treatment options ranging from a “watch-and-wait” approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411111/ https://www.ncbi.nlm.nih.gov/pubmed/28479860 http://dx.doi.org/10.2147/CMAR.S120589 |